Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14376 - 14400 of 14978 in total

3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile

Experimental

4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine

Experimental

LY-518674

LY518674 has been used in trials studying the treatment of Metabolic Syndrome X.
Investigational

Fazadinium bromide

Experimental

Daxalipram

Experimental

2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid

Experimental

9-Amino-2-deoxy-2,3-dehydro-n-acetyl-neuraminic acid

Experimental

1-((2-HYDROXYETHOXY)METHYL)-5-(PHENYLTHIO)PYRIMIDINE-2,4(1H,3H)-DIONE

Experimental

(R)-Atenolol

Experimental

N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE

Experimental

(5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE

Experimental

1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea

Experimental

(6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE

Experimental

3-[(4-CHLOROANILINO)SULFONYL]THIOPHENE-2-CARBOXYLIC ACID

Experimental

GLPG-0492

Glpg0492 is under investigation in clinical trial NCT01130818 (First-in-Human Single Ascending Dose of GLPG0492).
Investigational

Daniquidone

Daniquidone has been used in trials studying the treatment of Neoplasms.
Investigational

CHS-828

CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational

Esatenolol

Esatenolol is a beta blocker.
Experimental

CP-271485

Experimental

Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol

Experimental

(2R)-2-[(1R)-1-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-2-oxoethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid

Experimental

3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE

Experimental

Albendazole oxide

Experimental

APL-9

APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. APL-9 is designed...
Investigational
Matched Description: … mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and …

KB-141

An anticholesteremic agent.
Experimental
Displaying drugs 14376 - 14400 of 14978 in total